Bioatla announces change in executive leadership

San diego, feb. 27, 2023 (globe newswire) -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics for the treatment of solid tumors, today announced that its president, scott smith, will be leaving the company to pursue a new opportunity as chief executive officer at viatris (nasdaq: vtrs), a large, global healthcare pharmaceutical company. scott will continue his relationship with bioatla by serving as a board of directors member for the company.
BCAB Ratings Summary
BCAB Quant Ranking